GC Cell

GC Cell Debt

The Debt of GC Cell (144510.KQ) as of Nov 1, 2026 is 84.63 B KRW. In the previous year, Debt was 91.43 B KRW — a change of -7.44% (lower).

Debt

84.63 BKRW

YoY

-7.44%

Last updated:

In 2024, GC Cell's total debt was 84.63 B KRW, a -7.44% change from the 91.43 B KRW total debt recorded in the previous year.

The GC Cell Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
0.00 KRW
Jan 1, 2018
0.00 KRW
Jan 1, 2019
7.29 B KRW
Jan 1, 2020
7.13 B KRW
Jan 1, 2021
69.87 B KRW
Jan 1, 2022
75.05 B KRW
Jan 1, 2023
91.43 B KRW
Jan 1, 2024
84.63 B KRW
The GC Cell Debt history
YEARDebtYoY
84.63 BKRW-7.44%
91.43 BKRW+21.83%
75.05 BKRW+7.41%
69.87 BKRW+880.09%
7.13 BKRW-2.24%
7.29 BKRW—
0.00KRW—
0.00KRW—
0.00KRW—
0.00KRW—
0.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GC Cell Stock analysis

What does GC Cell do? GC Cell Corp generates revenue through four business segments. The Specimen Testing Service segment offers sample testing, clinical trial support, and veterinary testing services to clients in healthcare and research sectors. The Cell Therapy segment provides cell culture solutions and technology transfer services to biotechnology firms. The Cord Blood Storage segment delivers cord blood storage services primarily to expectant parents and medical institutions. The Other Business segment handles bio-logistics services and related operations for healthcare providers. The company's revenue streams are derived from direct contracts with healthcare organizations, biotech companies, and individual clients seeking specialized testing and storage solutions. Clients include hospitals, research institutions, and private individuals requiring cord blood preservation. The firm's business model focuses on providing specialized services within the life sciences sector without relying on external partnerships or third-party platforms. GC Cell Corp's product offerings are tailored to specific industry needs, with each segment targeting distinct client groups. The Specimen Testing Service segment serves clients needing laboratory analysis, while the Cell Therapy segment supports biotech innovation through technology transfer. The Cord Blood Storage segment caters to consumer demand for personal health preservation, and the Other Business segment facilitates logistics for medical supply chains. GC Cell is one of the most popular companies on Eulerpool.

Debt Details

Understanding GC Cell's Debt Structure

GC Cell's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing GC Cell's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to GC Cell’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in GC Cell’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about GC Cell stock

Debt of GC Cell is 84.63 B KRW in 2024.

Debt of GC Cell changed from 91.43 B KRW to 84.63 B KRW, representing a -7.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt GC Cell since 2006 – with annual values, charts, and detailed analysis.

Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's GC Cell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — GC Cell

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — GC Cell